
    
      Clinical Trial, phase IV, randomized, open label, multicenter with approved drugs in their
      use conditions.

      A switch to a regimen consisting of ATV/RTV 300/100 mg QD + 3TC 300 mg QD in HIV-1 infected
      subjects in their first antiretroviral regimen and who are virologically suppressed on a
      regimen which consists of 2 NRTIs + any 3rd agent, is non-inferior to continue or switch to
      ATV/RTV 300/100 mg QD + 2 optimized NRTIs for maintenance of virological suppression.
    
  